HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AP22408

structure in first source

Also Known As:

AP 22408

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Organophosphonates: 424
    - Diphosphonates: 11565
      - AP22408: 2

Experts

1.	Rucci, Nadia: 1 article (04/2008)
2.	Susa, Maria: 1 article (04/2008)
3.	Teti, Anna: 1 article (04/2008)
4.	Adams, Susan: 1 article (09/2003)
5.	Bohacek, Regine S: 1 article (09/2003)
6.	Dalgarno, David C: 1 article (09/2003)
7.	Keats, Jeffrey A: 1 article (09/2003)
8.	Keenan, Terence P: 1 article (09/2003)
9.	Liou, Shuenn: 1 article (09/2003)
10.	Liu, Shuangying: 1 article (09/2003)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 04/01/2008 - "The purine-based c-Src inhibitor AP23451 and the dual c-Src/Abl inhibitors AP22408 and AP23236 proved efficacious in reducing bone metastases in preclinical studies. "
2.	Osteoporosis 09/15/2003 - "The potential use of Src inhibitors for osteoporosis therapy has been previously shown by novel bone-targeted ligands of the Src SH2 (e.g., AP22408) and non-bone-targeted, ATP-based inhibitors of Src kinase. "

Related Drugs and Biologics

1.	AP 23451
2.	AP23236
3.	purine
4.	src-Family Kinases
5.	Ligands
6.	Adenosine Triphosphate (ATP)

Related Therapies and Procedures

1.	Therapeutics